TENEX (guanfacine hydrochloride) by Teva is clinical pharmacology guanfacine tablets, are an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central α 2 -adrenergic receptors. First approved in 1986.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
TENEX (guanfacine hydrochloride) is an oral antihypertensive agent approved in 1986 that works by stimulating central α2-adrenergic receptors to reduce sympathetic nerve impulses. It decreases peripheral vascular resistance and heart rate, resulting in blood pressure reduction in patients with mild to moderate hypertension. The drug is available as a tablet and can be used as monotherapy or in combination with other antihypertensives like thiazide diuretics.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and shift toward generic/lifecycle management strategies.
CLINICAL PHARMACOLOGY Guanfacine tablets, are an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central α 2 -adrenergic receptors. By stimulating these receptors, guanfacine reduces sympathetic nerve impulses from the vasomotor center to the…
Worked on TENEX at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective, Multicenter, RCT of the Tenex Ultrasound System
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
Teva is hiring 10 roles related to this product
The 57 linked jobs associated with TENEX skew heavily toward IT, supply chain, and digital roles rather than traditional pharma commercial functions, reflecting Teva's operational and technology infrastructure needs around this legacy product. Careers on TENEX emphasize operational efficiency and data management as the product matures toward LOE.
57 open roles linked to this drug